IDiyas

For the Inventor, By the Inventor

Needham, MA, United States of America

Matthew Gregory Bursavich

USPTO Granted Patents = 22 

 

Average Co-Inventor Count = 8.5

ph-index = 5

Forward Citations = 50(Granted Patents)


Company Filing History:

goldMedal15 out of 15 
 
Morphic Therapeutic, Inc.
 patents
silverMedal3 out of 8 
 
Axovant Sciences Gmbh
 patents
bronzeMedal2 out of 44 
 
Ironwood Pharmaceuticals, Inc.
 patents
4. 2 out of 51 
 
Denali Therapeutics Inc.
 patents

Years Active: 2017-2025

Loading Chart...
Loading Chart...
22 patents (USPTO):
1. 12459942 - Inhibiting (α-v)(β-6) integrin (2025-11-04),
2. 12415796 - Inhibitors of (αv)(β6) integrin (2025-09-16),
3. 12221416 - Antagonists of human integrin α4β7 (2025-02-11),
4. 12145935 - Inhibitors of (α-v)(β-6) integrin (2024-11-19),
5. 11827621 - Inhibitors of (α-v)(β-6) integrin (2023-11-28),
6. 11795167 - Inhibitors of (α-v)(β-6) integrin (2023-10-24),
7. 11739087 - Inhibiting (α-v)(β-6) integrin (2023-08-29),
8. 11370773 - Inhibiting human integrin (alpha-4) (beta-7) (2022-06-28),
9. 11174228 - Antagonists of human integrin (α4)(β7) (2021-11-16),
10. 11104661 - Inhibiting human integrin (α-4) (β-7) (2021-08-31),
11. 11046685 - Inhibitors of (α-v)(β-6) integrin (2021-06-29),
12. 11046669 - Inhibitors of (α-v)(β-6) integrin (2021-06-29),
13. 11040955 - Inhibitors of (alpha-v)(beta-6) integrin (2021-06-22),
14. 11021480 - Inhibiting (α-V)(β-6) integrin (2021-06-01),
15. 10759756 - Antagonists of human integrin α4β7 (2020-09-01),

Title: Matthew Gregory Bursavich: Innovator in Integrin Research

Introduction

Matthew Gregory Bursavich is a prominent inventor based in Needham, MA, known for his significant contributions to the field of integrin research. With a remarkable portfolio of 20 patents, Bursavich focuses on developing therapeutic strategies for various diseases through his innovative work on integrin antagonists and inhibitors.

Latest Patents

Bursavich's latest patents include groundbreaking work on small molecule antagonists of human integrin α4β7. These compounds offer potential treatments for a range of specific diseases or conditions. Additionally, he has developed small molecule inhibitors of the integrin αvβ6, expanding the scope of therapeutic options for various health issues.

Career Highlights

Throughout his career, Bursavich has worked with renowned organizations such as Morphic Therapeutics, Inc. and Axovant Sciences GmbH. His research contributions have been vital in pioneering new therapeutic approaches, positioning him as a leader in the biopharmaceutical industry. His dedication to addressing unmet medical needs through innovative solutions is evident in his extensive patent portfolio.

Collaborations

Bursavich has collaborated with talented professionals, including Bryce Alden Harrison and Aleksey I Gerasyuto. These partnerships reflect his commitment to advancing research and fostering innovative approaches within the scientific community.

Conclusion

Matthew Gregory Bursavich exemplifies the spirit of innovation in the field of integrin research. His 20 patents showcase his dedication to improving healthcare through targeted therapies, making a lasting impact on the industry and enhancing the lives of many patients. With continued efforts in research and collaboration, Bursavich is poised to contribute even further to medical advancements in the years to come.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…